HK1255100A1 - 用於抗肌萎縮蛋白外顯子53跳讀的有效基因治療工具 - Google Patents

用於抗肌萎縮蛋白外顯子53跳讀的有效基因治療工具

Info

Publication number
HK1255100A1
HK1255100A1 HK18114253.3A HK18114253A HK1255100A1 HK 1255100 A1 HK1255100 A1 HK 1255100A1 HK 18114253 A HK18114253 A HK 18114253A HK 1255100 A1 HK1255100 A1 HK 1255100A1
Authority
HK
Hong Kong
Prior art keywords
skipping
gene therapy
effective gene
dystrophin exon
therapy tools
Prior art date
Application number
HK18114253.3A
Other languages
English (en)
Inventor
佛朗斯‧彼得里-魯克塞爾
維爾日妮‧弗朗索瓦
Original Assignee
吉尼松公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 吉尼松公司 filed Critical 吉尼松公司
Publication of HK1255100A1 publication Critical patent/HK1255100A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18114253.3A 2015-12-09 2018-11-08 用於抗肌萎縮蛋白外顯子53跳讀的有效基因治療工具 HK1255100A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1562036A FR3044926B1 (fr) 2015-12-09 2015-12-09 Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
PCT/FR2016/053312 WO2017098187A1 (fr) 2015-12-09 2016-12-09 Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine

Publications (1)

Publication Number Publication Date
HK1255100A1 true HK1255100A1 (zh) 2019-08-02

Family

ID=55346032

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114253.3A HK1255100A1 (zh) 2015-12-09 2018-11-08 用於抗肌萎縮蛋白外顯子53跳讀的有效基因治療工具

Country Status (11)

Country Link
US (1) US10752898B2 (zh)
EP (1) EP3387130B1 (zh)
JP (1) JP6878433B2 (zh)
CN (1) CN108368508B (zh)
CA (1) CA3006515A1 (zh)
DK (1) DK3387130T3 (zh)
ES (1) ES2845214T3 (zh)
FR (1) FR3044926B1 (zh)
HK (1) HK1255100A1 (zh)
PT (1) PT3387130T (zh)
WO (1) WO2017098187A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019146621A1 (ja) * 2018-01-25 2019-08-01 国立大学法人大阪大学 ペリオスチンの発現量増加またはスプライシングバリアントの変化を伴う疾患の治療用医薬組成物
EP3815696A4 (en) * 2018-06-26 2022-11-30 Nippon Shinyaku Co., Ltd. COMPOSITION COMPRISING AN ANTISENSE OLIGONUCLEOTIDE AND ITS USE FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CA3108289A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
KR20210081322A (ko) 2018-08-02 2021-07-01 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
WO2021089736A1 (en) 2019-11-06 2021-05-14 Association Institut De Myologie Combined therapy for muscular diseases
CN113088531B (zh) * 2021-03-25 2023-10-17 四川省药品检验研究院(四川省医疗器械检测中心) 牛源性成分定量分析标准质粒、制备及检测方法及应用
CN113355409A (zh) * 2021-07-05 2021-09-07 北京华瑞康源生物科技发展有限公司 一种检测人dmd基因外显子拷贝数变异的引物及探针组合物和试剂盒
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
WO2023130959A1 (zh) * 2022-01-04 2023-07-13 广州瑞风生物科技有限公司 靶向USH2A pre-mRNA的snRNA及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
NZ600121A (en) 2001-11-13 2013-12-20 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
AU2002360291A1 (en) * 2001-12-17 2003-06-30 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
JP5054975B2 (ja) 2003-09-30 2012-10-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア アデノ随伴ウイルス（ａａｖ）の同源系統群、配列、それらを含有するベクターおよびそれらの用途
EP3228711A1 (en) 2004-06-28 2017-10-11 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
FR2874384B1 (fr) * 2004-08-17 2010-07-30 Genethon Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
JP5963678B2 (ja) * 2009-11-12 2016-08-03 ジ ユニバーシティ オブ ウェスタン オーストラリア 病状を治療するためのアンチセンス分子及び方法
CA2792696C (en) 2010-03-17 2020-01-07 Association Institut De Myologie Modified u7 snrnas for treatment of neuromuscular diseases
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
BR112014033004B1 (pt) * 2012-07-03 2021-10-19 Biomarin Technologies B.V. Oligonucleotídeo para tratamento de pacientes com distrofia muscular
JP2016502858A (ja) * 2012-12-20 2016-02-01 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィを処置するための改善されたエキソンスキッピング組成物
US20160040162A1 (en) * 2013-03-14 2016-02-11 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
US10131910B2 (en) * 2014-07-10 2018-11-20 Stichting Katholieke Universiteit Antisense oligonucleotides for the treatment of Usher syndrome type 2

Also Published As

Publication number Publication date
WO2017098187A1 (fr) 2017-06-15
FR3044926A1 (fr) 2017-06-16
DK3387130T3 (da) 2020-12-07
US10752898B2 (en) 2020-08-25
FR3044926B1 (fr) 2020-01-31
CA3006515A1 (fr) 2017-06-15
PT3387130T (pt) 2020-11-20
CN108368508B (zh) 2022-07-05
JP6878433B2 (ja) 2021-05-26
EP3387130A1 (fr) 2018-10-17
CN108368508A (zh) 2018-08-03
JP2019502376A (ja) 2019-01-31
US20180362980A1 (en) 2018-12-20
ES2845214T3 (es) 2021-07-26
EP3387130B1 (fr) 2020-11-11

Similar Documents

Publication Publication Date Title
HK1255100A1 (zh) 用於抗肌萎縮蛋白外顯子53跳讀的有效基因治療工具
HK1254230A1 (zh) Tat誘導的基於crispr/核酸內切酶的基因編輯
IL247663B (en) Antisense oligomers for skipping exon 51 in the human dystrophin gene
EP3871632C0 (en) COMPARATIVE TOOL FOR PLANNING ORTHODONTIC TREATMENTS
IL247581B (en) Genome editing without nucleases
IL284577A (en) Garden healing
GB201506509D0 (en) Nuclease-mediated genome editing
AU364986S (en) Toolbox
IL263892A (en) Exon skipping oligomers for muscular dystrophy
GB201520828D0 (en) Stirring tool
IL251701A0 (en) Oligonucleotides for editing genomic DNA
ZA201801641B (en) Ground support design tool
PL3244717T3 (pl) Narzędzie do uprawy roli
GB201707212D0 (en) Gene therapy for ciliopathies
ZA201808539B (en) Thickener feed distributor
ZA201900047B (en) Consumption-regulated feed block
GB201519001D0 (en) Robotic seat-cleaning apparatus
SG11201800699SA (en) Facility for distributing working gas
GB201513151D0 (en) Functional gene replacement therapy
TWM489108U (en) Machine tool driving stabilization structure
IL263085A (en) Garden healing
GB201616821D0 (en) Gene therapy
GB2541434B (en) Detachable tool assembly for screwdriver
GB201612105D0 (en) Gene therapy
GB201612104D0 (en) Gene therapy